Cipla receives US FDA approval for Icatibant Injectable 30mg/3mL
15 July 2020 -

Cipla Limited (BSE: 500087) (NSE: CIPLA EQ), an India-based pharmaceutical company, has received final approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Icatibant Injectable 30mg/3mL, it was reported on Tuesday.

The product is indicated for the treatment of acute hereditary angioedema attacks in adults 18 years of age and older.

Icatibant Injectable 30mg/3mL is an AP-rated generic version of Shire's Firazyr.